Latinos Play A Critical Role In Guiding The Future Policies Of The Oregon PDAB
In the ongoing efforts to make prescription medications more affordable, the establishment of Oregon’s Prescription Drug Affordability Board (PDAB) has the potential to stand as a significant development. Their future decisions must be guided by listening to patients and advocates alike. This is particularly critical for Latino communities — making up nearly 14% of the state’s population — which are uniquely vulnerable to changes in healthcare policy and prescription drug pricing.
Latino communities often rely heavily on community health centers and clinics for their healthcare services. According to the National Association of Community Health Centers, nearly 40% of patients at these centers are Latino. These centers are the lifelines for many, providing essential care in environments that are culturally sensitive and accessible. However, if the
PDAB’s decisions inadvertently lead to medication shortages or increase administrative burdens on these healthcare providers, the consequences could be dire. Overburdened community resources would result in reduced quality of care, exacerbating health disparities already faced by Latino patients.
Uncertainty about medication availability and affordability can significantly increase stress and anxiety among patients and that’s the case within the Latino community. The American Psychological Association notes that chronic stress is a well-documented risk factor that negatively impacts both physical and mental health. For individuals already managing chronic conditions — conditions more prevalent in Latino communities, such as diabetes and hypertension — the added stress of not knowing whether they can afford their next prescription can lead to worsening health outcomes and the emergence of new health issues. The Centers for Disease Control and Prevention (CDC) reports that Latinos are 1.7 times more likely than non-Hispanic whites to be diagnosed with diabetes and have higher rates of hypertension and obesity.
The PDAB’s decisions on critical drugs and therapies could be particularly disastrous for the Latino community if they impede access to medications that patients trust and rely on. Many in our community have long-standing relationships with specific medications that have proven effective in managing their health conditions. Disruptions in access to these medications can erode trust in the healthcare system and lead to detrimental health consequences.
It is heartening to note that the PDAB has shown a genuine interest in engaging with stakeholders. During its meeting in June, the board took a commendable step by suspending reviews to facilitate a quality discussion centered around affordability. This move signaled real progress and offers promising signs for the future. However, it is crucial that this engagement continues in a meaningful way as the board continues its work.
As the PDAB moves forward, I implore the board to maintain an open dialogue with patients and advocates — especially among the state’s Latino community. Listening to the voices of those directly impacted by these decisions is not just a courtesy but a necessity. Only through inclusive and empathetic policymaking can we hope to achieve an equitable healthcare system that serves everyone in the state, including the nearly 600,000 calling Oregon home.
The work of the PDAB holds great promise for making prescription medications more affordable. By prioritizing patient and advocate input, particularly from vulnerable communities, the board can ensure that its decisions do not inadvertently harm those they aim to help. Together, we can build a healthier, more inclusive and affordable future.
Joel Berrocal serves as the Executive Director of The National Puerto Rican Chamber of Commerce.
